Inhaled antiseptics and inhaled antiviral non-prescription drugs in the prevention of ARVI, in particular COVID-19: an epidemiological study
BACKGROUND. The article presents the results of a continuous, cross-sectional, non-interventional, multicenter retrospective epidemiological study, which included cases of 3443 participants. Questionnaires and rapid test for antibodies to SARS-CoV-2 were used to collect data.
OBJECTIVE. To determine the relationship between the systematic use of additional drugs for the prevention of COVID-19, including inhaled antiseptics and inhaled antiviral drugs, separately and in combination with other drugs, and the risk of developing of coronavirus disease (COVID-19).
RESULTS AND DISCUSSION. 396 participants (11.8 %) took inhaled antiseptics in any period since March 2020, and 410 participants (12.2 %) took inhaled antivirals. A statistically significant protective relationship between episode of COVID-19 when taking inhaled antiseptics and inhaled antiviral drugs (risk ratio 0.901; 95 % confidence interval 0.856-0.948) was determined.
CONCLUSIONS. The use of inhaled antiseptics and inhaled antiviral drugs as additional methods of prevention of COVID-19 has shown a statistically significant effect not only on reducing the risk of COVID-19, but different combinations of inhaled antiseptics or inhaled antiviral drugs with other drug groups as additional methods of preventing COVID-19 had a statistically significant protective relationship with the episode of the disease, with the severity of COVID-19 and with the need for hospitalization.
Fehr A.R., Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Coronaviruses. 2015 Feb 12; 1282: 1-23.
World Health Organization. Coronavirus disease (COVID-19). Available at: https://www.who.int/health-topics/coronavirus#tab=tab_1.
World Health Organization. Coronavirus disease (COVID-19) pandemic. Available at: https://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/novel-coronavirus-2019-ncov#:~:text=On%2031%20December%202019%2C,2019%2DnCoV”.
Sarah A., Dean O., Berk M. The evolution of clinical trials in response to COVID‐19. Med. J. Aust. 2021 Apr 19; 214 (7): 332.
Margolin L., Luchins J., Margolin D., Margolin M., Lefkowitz S. 20-week study of clinical outcomes of over-the-counter COVID-19 prophylaxis and treatment. J. Evid.-Based Integr. Med. 2021 Jan 1; 26: 1-13.
Castillo M.E., Costa L.M.E., Barrios J.M.V., Diaz J.F.A., Miranda J.L., Bouillon R., et al. Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: a pilot randomized clinical study. J. Steroid Biochem. Mol. Biol. 2020 Aug 29; 203: 105751.
Tan C.W., Ho L.P., Kalimuddin S., Cherng B.P.Z., Teh Y.E., Thien S.Y., et al. Cohort study to evaluate effect of vitamin D, magnesium, and vitamin B12 in combination on severe outcome progression in older patients with coronavirus (COVID-19). Nutrition. 2020 Sep 1; 79-80: 111017.
Institute for Work & Health. Selection bias. Available at: https://www.iwh.on.ca/what-researchers-mean-by/selection-bias.
Ukrainian Pravda. In Ukraine – the first case of coronavirus. Available at: https://www.pravda.com.ua/news/2020/03/3/7242332.
Ritchie H., Mathieu E., Rodes-Guirao L., Appel C., Giattino C., Ortiz-Ospina E., et al. Ukraine: coronavirus pandemic country profile. Available at: https://ourworldindata.org/coronavirus/country/ukraine.
Stepanov M. COVID-19. Available at: https://www.facebook.com/maksym.stepanov.official/posts/892476521295344.
Telegram. Coronavirus_info. Available at: https://t.me/s/COVID19_Ukraine.
Ministry of Finance. Vaccination against coronavirus in Ukraine. Available at: https://index.minfin.com.ua/ua/reference/coronavirus/vaccination/ukraine.
ClinicalTrials.gov. NCT05043142. Epidemiological study of the COVID-19 in participating organizations. Available at: https://register.clinicaltrials.gov/prs/app/action/SelectProtocol?sid=S000BC4T&selectaction=Edit&uid=U0003QLC&ts=2&cx=6gygw0.
DrugCentral. Decamethoxine. Available at: https://drugcentral.org/drugcard/4919.
Ulaizer. Ektobris. Available at: https://ulaizer.com.ua/ua/ektobris.
Compendium. (Akk). Available at: https://compendium.com.ua/dec/262140.
Compendium. Amixin® IC. Available at: https://compendium.com.ua/dec/267265.
Compendium. Amizon®. Available at: https://compendium.com.ua/dec/271524/?drugs=21760-93031.
Compendium. Inosinum Pranobex. Available at: https://compendium.com.ua/uk/akt/73/84923/inosinum-pranobex.
Compendium. Rimantadinum. Available at: https://compendium.com.ua/uk/akt/82/1517/rimantadinum.
Pharmacies of the Medical Academy. Umifenovirum. Available at: https://ama.dp.ua/assortiment/pharmgroop/24857.
Compendium. Nuclex. Available at: https://compendium.com.ua/dec/269918.
Compendium. Oseltamivirum. Available at: https://compendium.com.ua/uk/akt/79/33055/oseltamivirum.
Report of the clinical study EpidProtect-21 “Continuous, cross-sectional, non-interventional, multicenter retrospective epidemiological study of the incidence of COVID-19 and methods of prevention of ARVI, including COVID-19, among staff in participating organizations”, version 0.1, date: 28.06.2021.
Marik P. Critical care COVID-19 management protocol. Available at: https://www.sbk-vs.de/images/pdf/downloads/Corona/EVMS_Critical_Care_COVID-19_Protocol.pdf?m=1606470173&.
Ressing M., Blettner M., Klug S.J. Data analysis of epidemiological studies: part 11 of a series on evaluation of scientific publications. Dtsch Arztebl Int. 2010; 107 (11): 187-192.
Kumar G., Acharya A.S. Biases in epidemiological studies: how far are we from the truth? India J. Med. Specialities. 2014; 5 (1): 29-35.
Ministry of Health of Ukraine. Operational information on the spread and prevention of COVID-19. Available at: https://moz.gov.ua/article/news/operativna-informacija-pro-poshirennja-koronavirusnoi-infekcii-2019-cov19.
ClinicalTrials.gov. Prevention | Observational Studies | COVID-19. Available at: https://clinicaltrials.gov/ct2/results?term=prevention&type=Obsr&cond=-COVID-19&draw=2&rank=3#rowId2.
This work is licensed under a Creative Commons Attribution 4.0 International License.